Joint Formulary & PAD

Atorvastatin - Lipid modification

You are here : Home > Formulary Search > Atorvastatin - Lipid modification

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Green
Formulations :
  • Tablets
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
Guidelines
SPC
Restrictions / Comments :
Preferred
 

Status 2

Green (see narrative)
Formulations :
  • Chewable tablets
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
Guidelines
SPC
Restrictions / Comments :
Important

To be reserved for use in patients who cannot swallow tablets. 
Chewable tablets should be used in preference to atorvastatin oral suspension.
Not suitable for administration via feeding tube.

Documentation

Webpage
National Guidance for Lipid Management for Primary and Secondary Prevention of CVD (NHS England AAC programme)
Webpage
Statin Intolerance Pathway (NHS England AAC programme)
Webpage
NICE Clinical guideline [CG238] : Cardiovascular disease: risk assessment and reduction, including lipid modification

PAD Profile

ChemicalSubstance :
Atorvastatin
Indication :
Lipid modification
Group Name :
Keywords :
Statins, primary hypercholesterolaemia, mixed hyperlipidaemia, familial hypercholesterolaemia, high cholesterol, raised cholesterol, lipid lowering, lipid-lowering
Brand Names Include :
Lipitor
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Lipid modification
Supporting Documents :
3
Traffic Light Entries :
2

Committee Recommendations (3)

04 Feb 26 - Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands APC agreed that chewable atorvastatin tablets are a suitable treatment option for patients who are unable to swallow tablets. The chewable tablets should be used in preference to atorvastatin oral suspension.

NOT suitable for administration via a feeding tube.

03 May 17 - Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
GENERIC atorvastatin has been considered by the PCN and has been assigned a GREEN traffic light status.

NOTE - the branded product, Lipitor, was considered BLACK at the PCN in May 2017.
03 Sep 14 - Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)

NICE published CG 181 in July 2014 to update and replace NICE CG 67 and NICE TA 94 (statins for the prevention of cardiovascular events).

This latest guidance replaces all former Surrey guidance for lipid modification - see NICE CG 181 below.

If statin therapy is considered appropriate the guidelines recommend using atorvastin 20mg for primary prevention and atorvastatin 80mg for secondary prevention.

Other Indications

Below are listed other indications that Atorvastatin is used to treat.

  • No records returned.

Other Drugs

Below are listed other drugs that are used to treat Lipid modification.